2-Aryloxy-4-alkylaminopyridines: Discovery of novel corticotropin-releasing factor 1 antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1385-1392

  Chen, Yuhpyng L ^a   Obach, R Scott ^a   Braselton, John ^a   Corman, Michael L ^a   Forman, James ^a   Freeman, Jody ^a   Gallaschun, Randall J ^a   Mansbach, Robert ^a   Schmidt, Anne W ^a   Sprouse, Jeffrey S ^a   Tingley III, F David ^a   Winston, Elizabeth ^a   Schulz, David W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLORO 2,6 DIMETHYLPHENOXY) 4 (1 HYDROXYMETHYLPROPYLAMINO) 6 METHYLNICOTINIC ACID METHYL ESTER; 2 (4 CHLORO 2,6 DIMETHYLPHENOXY) 4 (1 HYDROXYMETHYLPROPYLAMINO) 6 N DIMETHYLNICOTAMIDE; [3,6 DIMETHYL 2 (2,4,6 TRIMETHYLPHENOXY)PYRIDIN 4 YL](1 ETHYLPROPYL)AMINE; [3,6 DIMETHYL 2 (2,6 DIMETHYL 4 CHLOROPHENOXY)PYRIDIN 4 YL](1 ETHYLPROPYL)AMINE; CORTICOTROPIN RELEASING FACTOR 1 RECEPTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CP 376395; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; FOOD INTAKE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; RAT;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; AMINOPYRIDINES; ANIMALS; ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; CORTICOTROPIN-RELEASING HORMONE; DOGS; FASTING; HUMANS; INJECTIONS, INTRAVENOUS; LOCUS COERULEUS; MALE; PITUITARY GLAND; POSTPRANDIAL PERIOD; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STARTLE REACTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41649117497     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070579c     Document Type: Article

References (20)

1. (a) Vale, W.; Spiess, J.; Rivier, C.; Rivier; J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta endorphin. Science 1981, 213, 1394.
2. (b) Owens, M. J.; Nemeroff, C. B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 1991, 43, 425.
3. (a) Chen, Y. L.; Mansbach, R. S.; Winter, S. M.; Brooks, E.; Collins, J.; Corman, M. L.; Dunaiskis, A. R.; Faraci, W. S.; Gallaschun, R. J.; Schmidt, A.; Schulz, D. W. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3- d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist. J. Med. Chem. 1997, 40, 1749.
4. (b) Schulz, W. D.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins, J.; Corman, M.; Dunaiskis, A.; Faraci, S.; Schmidt, A.; Seeger, T.; Seymour, P.; Tingley, F. D., III; Winston, E. N.; Chen, Y. L.; Heym, J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10477.
5. (c) Mansbach, R. S.; Winston, E. N.; Chen, Y. L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 1997, 323, 21-26.
6. (d) Shaham, Y.; Erb, S.; Leung, S.; Buczek, Y.; Stewart, J. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology 1998, 137, 184.
7. (e) Iredale, P. A.; Alvaro, J. D.; Lee, Y.; Terwilliger, R.; Chen, Y. L.; Duman, R. S. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J. Neurochem. 2000, 74, 199.
8. (f) Arborelius, L.; Skelton, K. H.; Thrivikraman, K. V.; Plotsky, P. M.; Schulz, D. W.; Owens, M. J. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharmacol. Exp. Ther. 2000, 294, 588.
9. (g) Hikichi, T.; Akiyoshi, J.; Yamamoto, Y.; Tsutsumi, T.; Isogawa, K.; Nagayama, H. Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 2000, 33, 189.
10. (h) Le, A. D.; Harding, S.; Juzytsch, W.; Watchus, J.; Shalev, U.; Shaham, Y. The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology 2000, 150, 317.
11. (i) Maillot, C.; Million, M.; Wei, J. Y.; Gauthier, A.; Tache, Y. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology 2000, 119, 1569.
12. Webster, E. L.; Lewis, D. B.; Torpy, D. J.; Zachman, E. K.; Rice, K. C.; Chrousos, G. P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRF) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996, 137, 5747.
13. (b) Bornstein, S. R.; Webster, E. L.; Torpy, D. J.; Richman, S. J.; Mitsiades, N.; Igel, M.; Lewis, D. B.; Rice, K. C.; Joost, H. G.; Tsokos, M.; Chrousos, G. P. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 1998, 139, 1546.
14. (c) Deak, T.; Nguyen, K. T.; Ehrlich, A. L.; Watkins, L. R.; Spencer, R. L.; Maier, S. F.; Licinio, J.; Wong, M. L.; Chrousos, G. P.; Webster, E.; Gold, P. W. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999, 140, 79.
15. Chen, Y. L.; Braselton, J.; Forman, J.; Gallaschun, R. J.; Mansbach, R.; Schmidt, A.; Seeger, T. F.; Sprouse, J.; Tingley, F. D.; Winston, E.; Schulz, D. W. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotrophin-releasing factor 1 antagonists. J. Med. Chem. 2008, ASAP Article, DOI: 10.021/jm070578k.
16. Unpublished data. A representative compound in pyrrolo[2,3-d] pyrimidine series, e.g., 2-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl7 H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-(S)-butan-1-ol, was found to produce liver toxicity in 90 day toxicology studies in rats and dogs.
17. Chen, C.; Grigoriadis, D. E. NBI 30775 (R121919), an orally active antagonist of the corticotropin-releasing factor (CRF) type-1 receptor for the treatment of anxiety and depression. Drug Dev. Res. 2005, 65, 216.
18. Unpublished phase I data.
19. Because the pyridine N-oxide intermediates may show exothermic decomposition, it is recommended to test the differential scanning calorimeter prior to scale-up synthesis. Pyridine N-oxide intermediates are not recommended for large-scale preparation, and caution is required to ensure safety in the laboratory. In general, a 100°C difference between process temperature and decomposition temperature is considered to be acceptable.
20. Chlorination yield was improved in the presence of 1 equiv of N,N-diethylaniline. Croisy-Delcey, M.; Bisagni, E. Aza analogs of lucanthone: synthesis and antitumor and bactericidal properties. J. Med. Chem. 1983, 26, 1329.